 |
|
|
|
|
|
|
|
|
|
|
 |
|
|||||||||
 |
 |
 |
 |
 |
 |
 |
 |
|
||
 |
 |
 |
|
|||||||
 |
|
|||||||||
 |
|
|||||||||
Alert Number 256
Date: October 14, 2024
All too often, the emphasis of research and clinical trials is focused on newly diagnosed or “naïve” ( = previously untreated) patients. But the grim reality is that except for a minority of exceptionally lucky CLL patients with truly smoldering disease that never needs treatment, for most of us the disease will progress over time and will need therapy to control it.
The latest article on our website, Refractory CLL, is all about the choices and risks faced by patients who are fludarabine refractory (and potentially some of these guys are Campath ineligible as well). If you are the type that would rather know what you are facing straight up, read on. Frankly, I do not see how else one can make smart therapy choices. But if you are feeling a tad vulnerable right now, it is not a bad idea to bookmark this article for reading at a later time. But do read it at some point – I would not want you to walk into this minefield with eyes tight shut.
Be well,
Chaya
_____
NOTICE: This page from the Topics Alert archive was originally emailed to subscribers of Topics Alert, a free service of CLL Topics Inc. If you are not a subscriber and you wish to receive email Alerts, please register at the Topics Alert subscription page. The content of this page is intended for information only and it is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
———
Disclaimer: The content of this website is intended for information only and is NOT meant to be medical advice. Please be sure to consult and follow the advice of your doctors on all medical matters.
Copyright Notice:
Copyright © 2024-2007 CLL Topics, Inc. All Rights Reserved.
All materials contained on this site are protected by United States copyright law and may not be reproduced, distributed, transmitted, displayed, published or broadcast without the prior written permission of CLL Topics, Inc. You may not alter or remove any trademark, copyright or other notice from copies of the content.
However, you may download and print material from CLLTopics.org exclusively for your personal, noncommercial use.
———
